Bayer Yakuhin Ltd - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Operational KPI's, and Recent Trends
Company Report I 2025-06-20 I 72 Pages I Quaintel Research
Report Summary
Bayer Yakuhin Ltd - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Operational KPI's, and Recent Trends is a comprehensive and easily accessible overview of Bayer Yakuhin Ltd 's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Bayer Yakuhin Ltd including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Bayer Yakuhin Ltd's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. By integrating these strategic analyses, the report offers a comprehensive understanding of Bayer Yakuhin Ltd's overall strategic standing and supports informed decision-making and strategic planning.
Finally, the report includes recent news and deal activities undertaken by Bayer Yakuhin Ltd enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Bayer Yakuhin, Ltd. is a leading Japanese pharmaceutical company and a wholly owned subsidiary of Bayer AG, the global life sciences enterprise headquartered in Germany. The company was established in April 1973 and has since played a key role in advancing Bayer's pharmaceutical presence in the Japanese market. With a strong emphasis on research, innovation, and patient well-being, Bayer Yakuhin has developed a robust portfolio that spans a range of therapeutic areas and medical technologies.
The company's headquarters are located in Kita-ku, Osaka, Japan. From this central location in Osaka, Bayer Yakuhin oversees its operations, strategy, and collaboration with domestic and international partners. It also manages activities at its manufacturing facility, known as the Supply Center Shiga, situated in Koka-shi, Shiga Prefecture. This plant plays a critical role in the production and quality control of pharmaceuticals distributed both locally and globally.
Bayer Yakuhin operates through two primary business divisions: Pharmaceuticals and Consumer Health. The Pharmaceuticals division focuses on therapeutic areas such as cardiovascular diseases, nephrology, oncology, ophthalmology, women's healthcare, hematology, and radiology. Meanwhile, the Consumer Health division supports daily wellness and offers over-the-counter products for common health concerns and preventive care, particularly emphasizing women's health.
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a Bayer Yakuhin Ltd's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the Bayer Yakuhin Ltd's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Company Fundamentals:- These fundamentals offer valuable insights into the Bayer Yakuhin Ltd's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the Bayer Yakuhin Ltd's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the Bayer Yakuhin Ltd's internal and external factors through SWOT analysis and Corporate Strategy.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Bayer Yakuhin Ltd:
- Bayer Yakuhin Ltd PESTLE Analysis
- Bayer Yakuhin Ltd Value Chain Analysis
- Bayer Yakuhin Ltd Porter's Five Forces Analysis
- Bayer Yakuhin Ltd VRIO Analysis
- Bayer Yakuhin Ltd BCG Analysis
- Bayer Yakuhin Ltd Segmentation, Targeting and Positioning (STP) Analysis
- Bayer Yakuhin Ltd Ansoff Matrix Analysis
Table of Contents
Table of Contents 2
Tables 4
Charts 5
Bayer Yakuhin Ltd - Key Company Facts 6
Bayer Yakuhin Ltd - Company Description 7
Bayer Yakuhin Ltd - Top Executives 8
Bayer Yakuhin Ltd - Head Office & Locations 9
Head Office - Country 9
Bayer Yakuhin Ltd - Products and Services 10
Products 10
Services 12
Bayer Yakuhin Ltd - Corporate Strategy 13
Bayer Yakuhin Ltd - Business Description 16
Pharmaceuticals Segment 16
Consumer Health Segment 17
Bayer Yakuhin Ltd - ESG Spotlight 18
Environment 18
Social 19
Corporate Governance 19
Bayer Yakuhin Ltd - SWOT Analysis 21
Overview 21
Strengths 23
Weaknesses 24
Opportunities 25
Threats 26
Competing Players 27
Snapshot of Competing Players 28
Astellas Pharma Inc. 28
Key Company Facts 28
Company Description 28
Astellas Pharma Inc. - SWOT Spotlight 29
Astellas Pharma Inc. - PESTLE Spotlight 31
Key Financials 33
Share Price Trend - Jan-2024 to Jun-2025 (Average Share Closing Price) 33
Key Financial Ratio Analysis 38
Chugai Pharmaceutical Co Ltd 39
Key Company Facts 39
Company Description 39
Key Financials 40
Share Price Trend - Feb-2024 to Jun-2025 (Average Share Closing Price) 40
Daiichi Sankyo Company Limited 42
Key Company Facts 42
Company Description 42
Daiichi Sankyo Company Limited - SWOT Spotlight 43
Daiichi Sankyo Company Limited - PESTLE Spotlight 45
Key Financials 47
Share Price Trend - Jan-2024 to Jun-2025 (Average Share Closing Price) 47
Key Financial Ratio Analysis 52
Key Financials 53
Share Price Trend - Jun-2024 to Jun-2025 (Average Share Closing Price) 53
Takeda Pharmaceutical Company Limited 55
Key Company Facts 55
Company Description 55
Takeda Pharmaceutical Company Limited - SWOT Spotlight 56
Takeda Pharmaceutical Company Limited - PESTLE Spotlight 58
Key Financials 60
Share Price Trend - Jan-2024 to Jun-2025 (Average Share Closing Price) 60
Key Financial Ratio Analysis 65
Bayer Yakuhin Ltd - In the News 66
08-Feb-2023- Bill Anderson to become CEO of Bayer AG 66
Appendix 69
Definitions 69
SWOT Analysis 69
PESTLE Analysis 69
Value Chain Analysis 69
ESG Spotlight 69
Research Methodology 70
Disclaimer 71
Contact Us 71
Tables
Table 1: Bayer Yakuhin Ltd - Company Facts
Table 2: Bayer Yakuhin Ltd - Digital Presence
Table 3: Bayer Yakuhin Ltd - Top Executives
Table 4: Bayer Yakuhin Ltd - Products
Table 5: Bayer Yakuhin Ltd - Services
Table 6: Bayer Yakuhin Ltd -Competing Players
Table 7: Competing Players - Astellas Pharma Inc. - Key Company Facts
Table 8: Astellas Pharma Inc. - Share Price Trend - Jan-2024 to Jun-2025
Table 9: Competing Players - Astellas Pharma Inc. - Profit and Loss Statement
Table 10: Astellas Pharma Inc. - Balance Sheet 2021-2024
Table 11: Astellas Pharma Inc. - Cash Flow Statement 2021-2024
Table 12: Astellas Pharma Inc. - Ratio Analysis - 2021-2024
Table 13: Competing Players - Chugai Pharmaceutical Co Ltd - Key Company Facts
Table 14: Chugai Pharmaceutical Co Ltd - Share Price Trend - Feb-2024 to Jun-2025
Table 15: Competing Players - Daiichi Sankyo Company Limited - Key Company Facts
Table 16: Daiichi Sankyo Company Limited - Share Price Trend - Jan-2024 to Jun-2025
Table 17: Competing Players - Daiichi Sankyo Company Limited - Profit and Loss Statement
Table 18: Daiichi Sankyo Company Limited - Balance Sheet 2021-2024
Table 19: Daiichi Sankyo Company Limited - Cash Flow Statement 2021-2024
Table 20: Daiichi Sankyo Company Limited - Ratio Analysis - 2021-2024
Table 21: Otsuka Holdings Co. Ltd - Share Price Trend - Jun-2024 to Jun-2025
Table 22: Competing Players - Takeda Pharmaceutical Company Limited - Key Company Facts
Table 23: Takeda Pharmaceutical Company Limited - Share Price Trend - Jan-2024 to Jun-2025
Table 24: Competing Players - Takeda Pharmaceutical Company Limited - Profit and Loss Statement
Table 25: Takeda Pharmaceutical Company Limited - Balance Sheet 2021-2024
Table 26: Takeda Pharmaceutical Company Limited - Cash Flow Statement 2021-2024
Table 27: Takeda Pharmaceutical Company Limited - Ratio Analysis - 2021-2024
Charts
Figure 1: Bayer Yakuhin Ltd - SWOT Analysis
Figure 2: Competing Players - Astellas Pharma Inc. - SWOTSpotlight
Figure 3: Competing Players - Astellas Pharma Inc. - PESTLE Spotlight
Figure 4: Astellas Pharma Inc. - Average Share Price Trend -Jan-2024 to Jun-2025
Figure 5: Astellas Pharma Inc. - Profit and Loss Statement - 2021-2024
Figure 6: Astellas Pharma Inc. - Balance Sheet - 2021-2024
Figure 7: Astellas Pharma Inc. - Cash Flow Statement 2021-2024
Figure 8: Chugai Pharmaceutical Co Ltd - Average Share Price Trend -Feb-2024 to Jun-2025
Figure 9: Competing Players - Daiichi Sankyo Company Limited - SWOTSpotlight
Figure 10: Competing Players - Daiichi Sankyo Company Limited - PESTLE Spotlight
Figure 11: Daiichi Sankyo Company Limited - Average Share Price Trend -Jan-2024 to Jun-2025
Figure 12: Daiichi Sankyo Company Limited - Profit and Loss Statement - 2021-2024
Figure 13: Daiichi Sankyo Company Limited - Balance Sheet - 2021-2024
Figure 14: Daiichi Sankyo Company Limited - Cash Flow Statement 2021-2024
Figure 15: Otsuka Holdings Co. Ltd - Average Share Price Trend -Jun-2024 to Jun-2025
Figure 16: Competing Players - Takeda Pharmaceutical Company Limited - SWOTSpotlight
Figure 17: Competing Players - Takeda Pharmaceutical Company Limited - PESTLE Spotlight
Figure 18: Takeda Pharmaceutical Company Limited - Average Share Price Trend -Jan-2024 to Jun-2025
Figure 19: Takeda Pharmaceutical Company Limited - Profit and Loss Statement - 2021-2024
Figure 20: Takeda Pharmaceutical Company Limited - Balance Sheet - 2021-2024
Figure 21: Takeda Pharmaceutical Company Limited - Cash Flow Statement 2021-2024
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.